PHYSICIAN-LED TEAM OF EXPERTS
GreenLight Clinical was founded and continues to be run by a group of highly-regarded physicians & researchers with multi-disciplinary skillsets. All have a proven track record in delivering high-quality research outputs.
Our experienced, knowledgeable clinical trial experts provide the highest quality research outcomes for our partners. As a full-service provider, our teams cover all aspects of clinical trial management, drug & device development and global regulatory affairs.
Director, Chairman of the Board
Andrew Chang – MBBS(Hons), Ph.D. (USyd), FRANZCO, FRACS
Associate Professor Andrew Chang is a vitreoretinal surgeon and ophthalmologist. Dr. Chang holds an academic appointment as a Clinical Associate Professor at the University of Sydney.
Dr. Chang is a Consultant Vitreoretinal Surgeon and the Head of the Retinal Unit at the Sydney Eye Hospital. He is the Medical Director of Sydney Retina Clinic.
Graduating from the University of Sydney Medical School, Dr. Chang underwent ophthalmology training at the Sydney Eye Hospital and fellowship training at Royal Victorian Eye & Ear Hospital and in the United States. He was awarded a Ph.D. for research into retinal and choroidal angiography performed in the Universities of California and Sydney.
Dr. Chang’s commitment to international ophthalmology includes the Secretary-General of the Asia-Pacific Vitreoretinal Society (APVRS). He is a clinician advisor to the Department of Health Australia. He is a Director of the RANZCO Board and the Sydney Eye Hospital Foundation Board. Professional awards include the Achievement Award and Distinguished Service Award of the Asia Pacific Academy of Ophthalmology (APAO) & the RANZCO Excellence in Teaching Award.
Dr. Chang is enthusiastically involved in basic science & clinical trials research, receiving research grant funding in Australia and the USA. His research is extensively published in peer-reviewed scientific literature. He serves on the editorial boards of scientific peer-reviewed journals including Clinical & Experimental Ophthalmology.
In wider healthcare activities, Dr. Chang is engaged in the complexities of modern hospital healthcare delivery. He supports new medical drugs & devices by engaging in clinical trials development. He drives strategies to improve patient engagement with healthcare professionals, using the latest in cloud, IoT & Artificial Intelligence.
Interim CEO & Group General Counsel
Franz D’Lima has over 20 years of global corporate experience in senior management positions. They include senior general counsel positions in global FMCG, Healthcare & B2B industries. Franz’s diverse experience in ANZ, EMEA & APAC (including the emerging markets of China & India), has helped him develop an acute understanding of the business and legal environments in multiple jurisdictions. He has a deep appreciation of cross-cultural sensitivities.
Franz approaches all issues from a commercial perspective. He has acquired a reputation as a trusted business partner. He’s managed several complex projects, including the successful transition of a US$100M healthcare business in Japan, the divestment of multi-million dollar cigarette paper businesses in Indonesia and the Philippines.
Franz also established manufacturing facilities and R&D centres across the Asia Pacific region.
He’s successfully led and defended multifaceted legal actions against the government and quasi-government agencies most notably in China, Korea, the Philippines and Thailand.
Franz is a qualified lawyer in both England & Wales, and New South Wales, Australia. He specialises in M&A, divestments, strategic alliances, intellectual property, data privacy, anti-bribery, risk and compliance management.